Pieris Pharmaceuticals, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017; filed May 15, 2017. The filing is for Pieris Pharmaceuticals, Inc., although the request metadata names Palvella Therapeutics, Inc. Verify the intended company.
Business context
Pieris is a clinical-stage biopharmaceutical company developing Anticalin protein-based medicines. It has no product sales; reported revenue comes principally from collaboration and licensing arrangements and research services. Key programs include PRS-343 and other 300-Series oncology candidates, PRS-080 for anemia, and PRS-060 for asthma.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Revenue | $1.34 million | $1.25 million |
| Research and development expense | $5.36 million | $3.66 million |
| General and administrative expense | $3.99 million | $1.97 million |
| Operating loss | $8.01 million | $4.38 million |
| Net loss | $7.99 million | $4.16 million |
| Basic and diluted net loss per share | $0.19 | $0.10 |
| Operating cash flow | $25.77 million provided | $2.03 million provided |
Revenue rose 8%, reflecting recognition of Servier upfront consideration, partly offset by lower Roche research revenue. R&D expense increased 46%, mainly from PRS-300-Series and PRS-060 activity. G&A roughly doubled, with higher personnel and professional-service costs, including success fees. Losses widened; product margins are not applicable because Pieris had no product sales.
Cash was $55.24 million at March 31, up from $29.36 million at year-end. The cash-flow statement reports operating cash provided of $25.77 million, largely reflecting a $33.52 million increase in deferred revenue; this is not recurring operating profitability. Investing cash use was $0.18 million, and no financing cash flow was reported. Total liabilities were $43.84 million, including $37.52 million of current and long-term deferred revenue; the filing reports no debt balance. Accumulated deficit was $110.66 million.
Management said cash at quarter-end plus $57.5 million expected from AstraZeneca after quarter-end would fund its current operating plan for at least 12 months from filing. The filing also states additional capital may be needed. Its liquidity discussion refers to $32.3 million received from Servier, while the agreement note describes €30.0 million, approximately $32.0 million.
Material developments, outlook and risks
- Servier: The January collaboration covers five initial bispecific programs, led by PRS-332, with potential expansion. Pieris received a nonrefundable €30.0 million upfront payment; substantial development, regulatory and sales milestones and royalties are contingent. Q1 Servier revenue was $0.3 million; $31.8 million was deferred at March 31.
- ASKA: A February option agreement provided a $2.75 million upfront payment for potential PRS-080 rights in Japan and certain Asian territories. It remained deferred at quarter-end; revenue is expected upon delivery of Phase 2a study results. Pieris must complete the study and faces a contractual penalty for failure.
- AstraZeneca (subsequent event): Agreements signed May 2 cover up to five inhaled biologic programs, including PRS-060. Pieris is to receive $57.5 million in upfront and near-term milestone payments, including $45 million upfront and $12.5 million upon Phase 1 initiation; further milestones could total up to $2.1 billion. These amounts were subsequent to quarter-end, not Q1 revenue or quarter-end cash.
- Program outlook: Management planned to initiate a PRS-343 Phase 1 trial in the first half of 2017; expected to nominate a PRS-332 development candidate and begin IND-enabling work in the second half; planned a PRS-080 multidose study in Q2; and targeted first-in-human PRS-060 work in the second half. These are plans, not assured outcomes.
- Daiichi Sankyo: On May 8, the partner gave notice terminating the DS-9001a/PCSK9 program for strategic and commercial reasons. The filing says Phase 1 results showed no safety concern precluding development and LDL-C reduction, but Pieris had not yet determined its next steps. The collaboration continues for a second, undisclosed target.
- Risks and controls: Pieris expects continued substantial losses and R&D spending; future funding may be unavailable or dilutive, and delays or adverse clinical, regulatory, currency, or collaboration developments could affect liquidity and operations. Management reported effective controls at March 31 and said it remediated a prior material weakness in technical accounting for complex transactions. No material risk-factor changes were reported.
Investor verification priorities
- Confirm the filing’s issuer identity, given the mismatch with the request metadata.
- Track receipt and conditions of AstraZeneca’s post-quarter payments and reconcile these with the stated cash runway.
- Verify clinical progress and timelines for PRS-343, PRS-080, PRS-060, and PRS-332, including the required PRS-080 results delivery to ASKA.
- Assess the effect of DS-9001a’s termination and any resulting program transfer or future investment decision.
- Monitor collaboration revenue recognition and deferred-revenue balances, which drove reported positive operating cash flow despite the net loss.
- Review future financing needs, dilution risk, and the significant contingent nature of milestone and royalty opportunities.